The FDA on May 8, 2020, granted accelerated approval to RETEVMO® for the following indications:
1) Adult patients with metastatic RET fusion-positive Non-Small Cell Lung Cancer (NSCLC).
2) Adult and pediatric patients 12 years of age or older with advanced or metastatic RET-mutant Medullary Thyroid Cancer (MTC) who require systemic therapy.
3) Adult and pediatric patients 12 years of age or older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy, and who are Radioactive Iodine-refractory (if Radioactive Iodine is appropriate).
RETEVMO® is a product of Eli Lilly and Company.
